Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

 Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

Shots:

  • The PIONEER-HF 4-week extension study involves assessing Entresto vs Enalapril in ~832 patients with systolic heart failure treated with Entresto for the first 8 wks.& the last 4wks and with enalapril and then switched to Entresto for the last 4wks.
  • The PIONEER-HF 4-week extension study results: change in NT-proBNP (-18.5% vs -35.8%); symptomatic hypotension (2.9% vs 3.9%); hyperkalemia (2.4% vs 4.1%); Worsening renal function (8.6% vs 9.6%); no angioedema events; @12 wks. relative risk reduction 33%
  • Entresto (sacubitril/valsartan, bid, 50/100/200 mg) is a heart failure therapy used to reduce the strain on failing heart by improving neurohormonal systems and inhibiting the effect of overactive RAAS

Click  here to read full press release/ article | Ref: Novartis | Image: Daily Record 

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post